Alteogen Inc.
196170
株式のランク
#1844
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
株価
$165.61
時価総額
$11.53B
変化（1日）
4.13%
変化（1年）
-46.48%
国
KR
取引 Alteogen Inc. (196170)
カテゴリー
Healthcare
Alteogen Inc.（196170）の発行済株式数
June 2026 時点の発行済株式数 73.51M
Alteogen Inc. の最新の財務報告および株価によると、現在の発行済株式数は 73.51M です。December 2023 の終わりには、同社は 51.66M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Alteogen Inc.（196170）の発行済株式数の履歴（2012 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 73.51M | 38.40% |
| 2024 | 53.12M | 2.82% |
| 2023 | 51.66M | 0.74% |
| 2022 | 51.28M | -15.57% |
| 2021 | 60.74M | 20.48% |
| 2020 | 50.41M | 4.62% |
| 2019 | 48.19M | 5.97% |
| 2018 | 45.47M | 1.22% |
| 2017 | 44.92M | 3.62% |
| 2016 | 43.36M | 2.60% |
| 2015 | 42.26M | 34.26% |
| 2014 | 31.48M | 64.68% |
| 2013 | 19.11M | 15.04% |
| 2012 | 16.61M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 245.39% |
US
|
|
| 396.00M | 438.69% |
US
|
|
| 478.91M | 551.48% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -15.41% |
NL
|
